Program
elacestrant
Also written as “Elacestrant”, “RAD1901” and “Elacestrant dihydrochloride”.
Its studies are mostly in Breast Neoplasms · Hot Flashes, led by 3 companies.
Drug pageElacestrant: every studyAll 30 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Menarini Groupits history only | 95 open or running | phase 3since Dec 3, 2018 | Dec 31, 2014 | Nov 2026phase 2 · NCT05596409 |
| Radius Pharmaceuticalsits history only | 20 open or running | phase 2since Mar 6, 2009 | Mar 6, 2009 | none ahead |
| Criterium | 10 open or running | phase 2since Dec 30, 2020 | Dec 30, 2020 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Criterium only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2016Named elacestrantINNProposed as its International Nonproprietary Name in WHO's List 115 · before, RAD1901
- Dec 30, 2020First study: phase 2 study in Breast NeoplasmsFirst studyNCT04791384 · 5 enrolled · United States
TargetBeta
“An orally available, selective estrogen receptor degrader (SERD), with antineoplastic activity”NCIt, by rule
“Estrogen receptor alpha degrader; Estrogen receptor alpha degrader”ChEMBL 37, by rule
Other programs on ESR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Ethinyl Estradiolrule | Johnson & Johnson | phase 4 | 70 |
| Estradiolrule | Novo Nordisk | phase 4 | 69 |
| Fulvestrantrule | AstraZeneca | phase 4 | 30 |
| Tamoxifenrule | AstraZeneca | phase 4 | 21 |
| Clomiphenerule | Hamad Medical | phase 4 | 3 |
| vepdegestrantrule | Pfizer | phase 3 | 20 |
| camizestrantrule | AstraZeneca | phase 3 | 18 |
| giredestrant | Hoffmann-La Roche | phase 3 | 17 |
| HRS-8080 | Jiangsu HengRui Medicine | phase 3 | 13 |
| Imlunestrantrule | Eli Lilly | phase 3 | 12 |
| taragarestrantrule | InventisBio | phase 3 | 5 |
| SIM0270rule | Simcere Pharmaceutical Group | phase 3 | 5 |
Studies
The one study Criterium leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04791384Breast Neoplasms · United States | 2 | Terminated | Sep 16, 2024 | 5 |
How it is read
Names in the registry
- “Elacestrant”, 8 entries
- “RAD1901”, 6 entries
- “Elacestrant dihydrochloride”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 10 studies
- Hot Flashes, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.